August 13, 2013
Prior to joining CTI, Dr. Campaneria was with Inhibitex, a biopharmaceutical company, where he served as Medical Director, and led the development of several Hepatitis C programs. Dr. Campaneria also spent nearly ten years in multiple roles at Monitoring Force, an international Clinical Research Organization (CRO), conducting Phase II, III, and IV trials. Throughout his time with Monitoring Force, Dr. Campaneria managed global regulatory and clinical trial programs, and he held the position of Medical Monitor/Director, Director of Clinical Operations, and finally as CEO. Dr. Campaneria has worked in the CRO and Biopharmaceutical industry for the past ten years, and he has broad experience across the spectrum of drug development including medical monitoring, pharmacovigilance, project management, key opinion leader relationship development, medical evaluation risk assessment, drug safety reporting, regulatory filings, and regulatory document development. His therapeutic background includes industry and clinical experience in hematology, dermatology, immunology, infectious disease, and psychiatry. Dr. Campaneria earned his Doctor of Medicine from East Central University School of Medicine.
“We are very excited that Dr. Campaneria has joined our established medical team, as he brings a wealth of global clinical research and drug development experience in the biotech industry,” according to Lynn Fallon, Executive Vice President at CTI Clinical Trial and Consulting Services and President, Consulting Services. “His talents and knowledge are great compliments to the rest of our expert team of medical directors.”